Augmented post-remission therapy for a minimal residual disease-defined high-risk subgroup of children and young people with clinical standard-risk and intermediate-risk acute lymphoblastic leukaemia (UKALL 2003): A randomised controlled trial

Background: No randomised study has shown whether stratification of treatment by minimal residual disease (MRD) response improves outcome in children and young people with acute lymphoblastic leukaemia (ALL). We assessed whether children and young people with clinical standard and intermediate-risk...

Mô tả đầy đủ

Chi tiết về thư mục
Những tác giả chính: Vora, A, Goulden, N, Mitchell, C, Hancock, J, Hough, R, Rowntree, C, Moorman, A, Wade, R
Định dạng: Journal article
Ngôn ngữ:English
Được phát hành: Lancet 2014